We claim:

1. A candesartan cilexetil 1,4-dioxane solvate.
2. A candesartan cilexetil 1,4-dioxane solvate of claim 1, wherein the content of 1,4-dioxane is 8.8 to 13.0 % w/w.
3. A candesartan cilexetil 1,4-dioxane solvate of claim 1, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 6.0, 10.7, 16.2, 18.0, 19.7, 20.6, 21.3, 21.7, and 22.3 degrees.
4. Candesartan cilexetil 1,4-dioxane solvate of claim 3, further characterized by an x-ray powder diffraction pattern as in figure 1.
5. A process for the preparation of candesartan cilexetil 1,4-dioxane solvate of claim 1, which comprises:
   a) dissolving candesartan cilexetil in 1,4-dioxane; and
   b) crystallizing candesartan cilexetil as 1,4-dioxane solvate from the solution at 5^0C to 15^0C.
6. A process according to claim 5, wherein candesartan cilexetil used is a crystalline or amorphous form of candesartan cilexetil.
7. A process according to claim 6, wherein the crystalline form of candesartan cilexetil is candesartan cilexetil form III.
8. A crystalline candesartan cilexetil form III, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 6.3, 7.3, 8.1, 8.9, 10.1, 14.6, 15.0, 15.8, and 18.8 degrees.
9. Candesartan cilexetil form III of claim 8, further characterized by an x-ray powder diffraction pattern as in figure 2.
10. A process for the preparation of candesartan cilexetil form III of claim 8, which comprises:
    a) mixing candesartan cilexetil with toluene;
    b) heating to obtain clear solution;
    c) cooling slowly to 0^0C to 5^0C in about 1 hour;
    d) maintaining at 0^0C to 5^0C for about 1 hour; and
    e) filtering the separated solid.
11. A process according to claim 10, wherein candesartan cilexetil used is candesartan cilexetil as 1,4-dioxane solvate of claim 1.

12. A crystalline candesartan cilexetil form IV, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 6.1, 7.1, 11.6, 11.9, 17.9, 19.8 and 21.2 degrees.
13. Candesartan cilexetil form IV of claim 12, further characterized by an x-ray powder diffraction pattern as in figure 3.
14. A process for the preparation of candesartan cilexetil form IV of claim 12, which comprises:
    a) heating the mixture of candesartan cilexetil, methyl tert-butyl ether and methanol to 50^{0}C to 55^{0}C;
    b) cooling to 20^{0}C to 25^{0}C;
    c) maintaining at 20^{0}C to 25^{0}C for about 10 hours; and
    d) separated crystals are collected by filtration.
15. A process according to claim 14, wherein candesartan cilexetil used is a crystalline or amorphous or dioxane solvated form of candesartan cilexetil.
16. A process according to claim 15, wherein candesartan cilexetil used is candesartan cilexetil 1,4-dioxane solvate of claim 1.
17. A process according to claim 15, wherein candesartan cilexetil used is candesartan cilexetil form III of claim 8.
18. A pharmaceutical composition comprising candesartan cilexetil form III of claim 8 or candesartan cilexetil form IV of claim 12 and a pharmaceutically acceptable carrier.
19. A pharmaceutical composition of claim 18, wherein candesartan cilexetil form III is used.
20. A pharmaceutical composition of claim 18, wherein candesartan cilexetil form IV is used.